36215-07-3

Usage

Chemical Properties

Clear Colorless Liquid

Uses

1-Chloro-3-methoxypropane (cas# 36215-07-3) is a compound useful in organic synthesis.

InChI:InChI=1/C4H9ClO/c1-6-4-2-3-5/h2-4H2,1H3

Upstream product

• 74-85-1 ethene 
• 107-30-2 chloromethyl methyl ether 
• 627-30-5 1-chloro-3-hydroxypropane 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 109-70-6 1.3-chlorobromopropane 
• 106-89-8 epichlorohydrin 
• 186581-53-3 diazomethane 
• 77-78-1 dimethyl sulfate 
• 1589-49-7 methoxypropanol 
• 124-41-4 sodium methylate 

Downstream Products

• 61542-10-7 1-iodo-3-methoxypropane 
• 39216-84-7 2-(3-methoxy-propylamino)-ethanol 
• 137045-28-4 (3-methoxy-propyl)-malonic acid diethyl ester 
• 38624-41-8 4-methoxy-1-phenylbutan-1-ol 
• 138763-55-0 (3-Methoxypropyl)-triphenylphosphoniumchlorid 
• 182416-67-7 [2-(3-Methoxy-propoxy)-hex-5-enyloxy]-benzene 
• 857272-09-4 1-(3-methoxypropoxy)-2-nitrobenzene 
• 909406-81-1 4-bromo-2-(3-methoxypropoxy)-1-methylbenzene 
• 911706-55-3 6-[(3R,4R,6S)-4-[4-(3-methoxy-propoxy)-phenyl]-6-[(R)-2-(1H-tetrazol-5-yl)-propyl]-1-(toluene-4-sulfonyl)-piperidin-3-yloxymethyl]-4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo[1,4]oxazine 
• 911707-17-0 3-[(2S,4R,5R)-4-[4-(3-methoxy-propoxy)-phenyl]-5-[4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]-1-(toluene-4-sulfonyl)-piperidin-2-yl]-2,2-dimethyl-propionic acid 3-methoxy-propyl ester 
• 881192-37-6 (3-methoxypropyl)triphenylstannane 
• 1105675-89-5 2-(3-methoxypropylthio)benzenamine 
• 1358929-57-3 1-(4-iodophenyl)-4-methoxybutan-1-one 
• 2806-84-0 3-methoxy-1-propanal 

Relevant academic research and scientific papers

Synthesis, structural study, and in vitro trypanocidal and antitumour activities of tetrakis(3-methoxypropyl)tin and (3-methoxypropyl)tin chlorides

A set of four water-soluble (3-methoxypropyl)stannanes of general formula (CH3OCH2CH2CH2)x SnCl4-x, where x = 4 (1), x = 3 (2), x = 2 (3), and x = 1 (4), was prepared. For 3 and 4, which were isolated in the crystalline state, it was shown by X-ray diffraction that the tin atom is coordinated in distorted octahedral and trigonal-bipyramidal geometries, respectively (i.e., the oxygen atoms of the 3-methoxypropyl groups were coordinated to the central tin atom in both cases, forming chelates). For all compounds, structures in CDCl3 and [D6]DMSO solutions were proposed on the basis of their 13C and 119Sn NMR spectra. In CDCl3 solution, the degree of donor-acceptor bonding between the central tin atom and oxygen atom of the 3-methoxypropyl substituent was evaluated on the basis of 17O NMR chemical shifts and 3,6J(1H, 119Sn) long-range coupling constants. Compounds 2 and 3 exhibited promising in vitro antitumour and trypanocidal activities. Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2003.

Synthesis and catalytic testing of Lewis acidic nano zeolite Beta for epoxide ring opening with alcohols

Lewis acidic zeolites are robust catalytic materials that are capable of a range of important chemistry for fine chemical production, including the epoxide ring opening with alcohols. The crystalline structure imposes diffusion limitations for large molecules that are overcome through reducing the particle size to produce nano zeolite beta substituted with Lewis acidic tin (nSnBeta). nSnBeta is characterized using standard methods to demonstrate that tin is efficiently incorporated into the zeolite framework with open and closed sites similar to the micron-sized conventional Sn-Beta (cSnBeta). While nSnBeta exhibits comparable catalytic activity to cSnBeta for reactions involving small substrates such as epichlorohydrin and methanol, an improvement in catalytic performance is observed for nSnBeta relative to cSnBeta when using large substrates such as 1,2-epoxyoctane and ethanol. nSnBeta and cSnBeta convert a cyclic epoxide too large to enter the pores to similar extents, indicating that the improved performance is not associated with an increased number of catalytic sites on the external surface. Catalyst reuse experiments demonstrate that organic accumulation on the material reduces catalytic activity that can be partially restored through calcination. Overall, the results demonstrate that nano zeolite beta can be synthesized with small particle sizes (i.e., 150 nm) to help overcome diffusion limitations for bulky substrates for the alcohol ring opening of epoxides.

Asymmetric organocatalytic electrophilic phosphination

Meeting the challenge: The first asymmetric catalytic C*-P bond formation employing electrophilic phosphorus compounds has been developed using a catalytic amount of a dimeric cinchona alkaloid, and a subsequent one-pot process to deliver high stereoselectivities and good yields of α-quaternary α-phosphino β-amino acids (see scheme). 31P-NMR experiments suggest a novel reaction mechanism wherein a cinchona alkaloid nucleophilically activates the phosphorus electrophile. Copyright

Spirocyclic Cyclohexane Compounds

Spirocyclic cyclohexane compounds corresponding to formula I In which R1, R2, R3 and R5 through R10 and X have defined meanings, a process for their preparation, pharmaceutical compositions containing such compounds, and the use of such spirocyclic cyclohexane compounds in the treatment and/or inhibition of pain and other conditions mediated by the ORL-1 or the ?-opioid receptor.

INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING

A bisphosphonoaminc compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.

Spirocyclic Azaindole Derivatives

The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments.

INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING

A bisphosphonoamine compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.

EFFICIENT AND/OR SELECTIVE METHYLATION BY DIAZOMETHANE OF ALCOHOLS, HALO ALCOHOLS, GLYCOLS, AMINO ALCOHOLS AND MERCAPTO ALCOHOLS WITH THE USE OF A PROTON-EXCHANGED X-TYPE ZEOLITE AS AN ACID-BASE BIFUNCTIONAL CATALYST

Reactions of diazomethane with butanol, allyl alcohol and β- and γ-halo alcohols led to efficient methylation (giving the corresponding methyl ethers) with the use of a proton-excahnged X-type zeolite compared with H2SO4.The reactions with propylene and isobutylene glycols using the zeolite provided regioselective methylation of the primary OH rather than the secondary or tertiary OH, whereas regioselectivity was not observed in the reactions using H2SO4.The reactions with 2-aminoethanol and 2-mercaptoethanol showed high chemoselective S-methylation and N-monomethylation, respectively, in the presence of the zeolite instead of H2SO4.The mechanism for the reactions is proposed to involve acid-base bifunctional catalysis of the zeolite in which the acidic site reacts with diazomethane to form its conjugate acid, and the nucleophilicity of OH and SH groups is enhanced by the interaction of the basic site with the proton of the groups.

Kit for preparing a technetium-99m myocardial imaging agent

A myocardial imaging agent for use in humans comprising a Tc(III) complex ligated in a planar position by a tetradentate ligand having incorporated therein four hard atotms and two furanone rings and in the axial positions by phosphines containing dioxanyl or ether moieties. The agent exhibits improved biodistribution, improved labeling and extremely rapid blood clearance following administration to a human. The agent has high myocardial uptake accompanied with exceptionally rapid hepatobilary clearance and extensive renal clearance to give sufficiently high heart/liver and heart/lung ratio that provide nearly ideal myocardial images in humans. A kit for producing the myocardial imaging agent is provided.